Tilray 44% Down, Trulieve NYSE-Listed|Proxy Gone, What Holds the Stock?

The Structural Advantage That Just Disappeared

For years, Tilray held a position that no Canadian cannabis company earned through operations alone. Institutional investors who wanted cannabis exposure on a major US exchange had one option. They routed capital into Canadian operators like Tilray. American multi-state operators were confined to secondary Canadian exchanges or illiquid OTC markets. That structural bottleneck gave Tilray a premium embedded in its valuation. Not a premium tied to revenue. Not to margins. To access.

Trulieve Cannabis Corp. ended that arrangement on June 10, 2026. Trulieve became the first US plant-touching cannabis operator approved to list on the New York Stock Exchange. The mechanism was deliberate: Trulieve restructured into a medical-only consolidated entity. Federal reclassification of medical marijuana to Schedule III under the DEA made that restructuring viable. The exchange restrictions that blocked plant-touching operators from major US listings no longer apply to medical-only entities. Trulieve went through the gap.

The immediate implication for Tilray is not competitive in the product sense. Tilray and Trulieve do not primarily compete for the same consumer. The implication is institutional capital routing. Investors seeking a liquid, regulated cannabis position on a major US exchange no longer have to accept a Canadian operator as their proxy. They can now buy directly into a US operator with a domestic footprint. Trulieve operates in states where cannabis demand is direct and legal. Tilray's Canadian operations have no equivalent domestic US market access.

Tilray's stock is down 44% year to date as of June 10. Over five years, the stock has lost approximately 97% of its value. That trajectory predates the Trulieve uplisting. But the proxy premium that remained embedded in Tilray's valuation no longer has a structural basis to rest on.

The buried assumption the market has been pricing is worth naming. Many institutional holders of Tilray have implicitly treated the proxy premium as durable because the regulatory pathway to NYSE for US operators was blocked. That assumption required believing the Schedule III reclassification would not be fast enough or clean enough to produce NYSE-eligible US operators. Trulieve's successful listing demonstrates that assumption was wrong. The path was navigable within the regulatory framework that already exists. The floodgates, as one analysis published June 10 noted, are now officially open. Other multi-state operators are already executing reverse stock splits to prepare for their own major US exchange listings.

Atwater Divestment: Profitability Pivot or Asset Sale Under Pressure?

On June 4, 2026, Tilray announced it was selling Atwater Brewery back to its former owner Mark Rieth. The company framed the transaction as a profit-focused divestment. The logic: Atwater is a small-scale craft brewery that does not fit the scale economics Tilray is building toward in its beverage segment. Selling it frees resources for higher-margin operations.

That framing is one reading. The alternative reading starts from the same facts but draws a different conclusion. Tilray's beverage segment revenue in the most recent quarter was $65.6 million, down 14% year over year. The cannabis segment fell 6%. Net revenue for the quarter rose 11% to $206.7 million, but that growth was acquisition-driven. The operating loss was $26.4 million. Gross profit was $54.8 million on that revenue base — a 27% gross margin. General and administrative costs alone were $50.2 million in a single quarter. A business at 27% gross margin with G&A consuming almost all of that gross profit is not in a position to hold non-performing assets through a sentiment cycle.

The hidden assumption inside the profitability pivot narrative is that Tilray's management is cutting non-core assets because it has a clear path to operational cash flow generation without those assets. What the articles do not surface is that path. Tilray's full-year EBITDA guidance for fiscal 2026 ending May 31 is $62 million to $72 million adjusted. That range represents a 13% to 31% improvement from $55 million in fiscal 2025. But adjusted EBITDA excludes amortization, stock-based compensation, and non-recurring items. The company has not guided to positive free cash flow.

The Atwater sale, read alongside the Lyphe debt-for-equity transaction from earlier in the quarter, suggests a management team actively managing a balance sheet under constraint. Between April 1 and April 8, 2026, Tilray converted $12 million in convertible notes into 1,879,696 shares of common stock. The notes converted are the 5.20% Convertible Senior Notes due June 15, 2027. That maturity date is thirteen months away. Reducing the outstanding principal through equity conversions now reduces the cash obligation Tilray must meet at maturity. The transactions are described in public filings as reducing debt while increasing the equity base. They are also dilutive to existing shareholders. The sequence — sell an asset in June, convert notes in April — is consistent with a company managing liquidity toward a debt wall, not building excess capital.

The profitability pivot narrative and the liquidity management narrative are not mutually exclusive. Both can be true simultaneously. But a holder currently framing Tilray as a fundamentals improvement story needs to account for the 2027 notes maturity as a forward checkpoint. If the remaining convertible notes balance is not reduced further before June 2027, the cash outflow in that quarter becomes a constraint on all other capital allocation decisions.

The Question the Proxy Loss Forces

Tilray's case to institutional investors has operated on two separate levels. Level one is the operational thesis: cannabis demand grows, diversification into beverages creates a more durable revenue base, European medical cannabis exports are growing 73% year over year, and eventually US federal reform will open the largest cannabis market. Level two is the structural thesis: Canadian operators are the only accessible major-exchange proxy for institutional cannabis exposure.

The Trulieve NYSE listing eliminates level two entirely. What remains is level one, evaluated on its own merits. On that basis, Tilray's valuation at approximately $630 million today rests on a path to profitability that has not yet materialized in free cash flow terms, in a regulatory environment where US market access — the long-term growth driver — is now more directly accessible through US-domiciled operators.

The interpretation competition that now surrounds the stock is genuine. One group holds that the proxy loss is already priced into the 44% YTD decline. They argue that at a price-to-book ratio of approximately 0.4 times, the stock is pricing near liquidation value, which limits further downside. The adjusted EBITDA improvement trajectory — from $55 million to a guided $62 to $72 million — suggests the core business is modestly improving on a cash earnings basis. The Atwater divestment and debt reduction transactions are operational discipline, not distress.

The opposing group holds that the proxy premium was never fully priced out. As long as Trulieve's uplisting was theoretical, some portion of Tilray holders maintained their position on the premise that institutional alternatives were unavailable. That premise is now resolved. If those holders exit over the coming weeks, the price-to-book floor may be retested at a lower price level than current.

The forward checkpoint with the clearest timing is Tilray's fiscal year-end results, expected in late July or early August 2026 for the period ending May 31. Those results will be the first to include the Atwater divestment impact. The metric to watch is whether adjusted EBITDA comes in at the high end of the $62 to $72 million range. A result at or above $70 million, combined with evidence that convertible note reduction is continuing ahead of the June 2027 maturity, would support the profitability pivot narrative. A result below $65 million, combined with the proxy premium having exited the stock, would represent a structural re-rating at lower absolute levels.

The Chekhov anchor from the opening is the proxy premium. It existed because of a structural regulatory restriction. That restriction is now removed. The question the holding decision now faces is whether Tilray's improving EBITDA is fast enough and large enough to attract capital on fundamentals alone — in direct competition with US operators that now have equivalent exchange access and superior domestic market proximity. That is not resolved. It is the open question that the next quarterly result will begin to answer.